Dilip Shanghvi
Pharmaceuticals · Mumbai
Net worth
$27.1B
Today
−$120M−0.44%Past month
+$2.6B+10.72%As of Nov 11, 2026, 1:50 PM EST
The son of a pharmaceuticals distributor, Dilip Shanghvi borrowed $200 from his father to start Sun Pharmaceutical Industries in 1983 to make psychiatric drugs. The company is India's most valuable listed pharma outfit and gets two-thirds of its $6.1 billion annual revenue from overseas markets. He grew Sun through a series of acquisitions, the biggest of which was the 2014 purchase of scandal-tainted rival Ranbaxy Laboratories for $4 billion. Sun Pharma acquired U.S. skin cancer drug maker Checkpoint Therapeutics in May 2025 for $355 million. In February 2025, his son Aalok was appointed as chief operating officer of Sun Pharma.
Net worth over time
Principal holdings
4 positions| Company | Industry | Share | Value |
|---|---|---|---|
Sun Pharmaceutical Industries Ltd. BSE INDIA: 524715-IN | Healthcare | 94.4% | $25.6B |
Private and other holdings | Healthcare | 3.4% | $925M |
Sun Pharma Advanced Research BSE INDIA: 532872-IN | Healthcare | 1.7% | $465M |
Suzlon Energy Ltd. BSE INDIA: 532667-IN | Healthcare | 0.5% | $130M |
Also known for
- Photos of Shanghvi's family deity, Shrinathji, adorn Sun's factories and offices.
- Shanghvi 's favorite cuisine is south Indian.
- In 2023, Sun Pharma completed the $576 million acquisition of U.S.-based Concert Pharmaceuticals.
“Our story is all about incremental growth. We're not looking for big leaps; we prefer small jumps.”